GILD Earnings Prediction
The chart below shows how GILD performed 10 days before and after its earnings report, based on data from the past quarters. Typically, GILD sees a +1.37% change in stock price 10 days leading up to the earnings, and a +1.47% change 10 days following the report. On the earnings day itself, the stock moves by -0.44%. This data can give you a slight idea of what to expect for the next quarter's release.
GILD Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
7.54B
7.01%
8.50%
Gross Margin
79.14%
1.72%
1.72%
Operating Margin
42.03%
12.98%
8.13%
Net Margin
16.61%
-46.07%
-28.44%
EPS
1.00
-42.20%
-22.48%
No Data Available
GILD Earnings Analysis
Gilead Sciences Inc Corporation (GILD.O) Earnings Conference Call
Positive
Strong Revenue Performance: Gilead's third quarter results highlight strong year-over-year revenue performance across HIV, Oncology, and Liver Disease, including 9% growth in HIV.
Product Sales Growth: Total product sales, excluding Veklury, were $6.8 billion in the third quarter, up 7% year-over-year, reflecting strong growth across HIV, Oncology, and Liver Disease.
HIV Sales Increase: HIV sales of $5.1 billion were up 9% year-over-year and 7% sequentially, primarily driven by higher average realized price due to shifts in channel mix and higher demand across treatment and PrEP.
Biktarvy Sales Surge: Biktarvy third quarter sales of $3.5 billion increased 13% year-over-year, driven by higher demand as well as higher average realized price due to shifts in channel mix.
Strong 2024 Product Sales: Gilead is on track to deliver an extremely strong 2024, with expectations for full-year product sales in the range of $27.8 billion to $28.1 billion, an increase of $650 million at the midpoint compared to the prior range.
Negative
Strong Product Sales Growth: Total product sales, excluding Veklury, were $6.8 billion in the third quarter, reflecting a strong growth across HIV, Oncology, and Liver Disease.
Sales Growth Analysis: Sales of $5.1 billion were up 9% year-over-year and 7% sequentially, primarily driven by higher average realized price due to shifts in channel mix and higher demand across treatment and PrEP.
HIV Pricing Variability: The third quarter once again demonstrated the quarterly pricing variability we see in HIV, reflecting more favorable average realized pricing.
HIV Sales Growth Update: Year-to-date, HIV sales have grown 5%, well above our prior full-year growth target of 4%.
Operating Margin Analysis: The third quarter operating margin was 43%, excluding the impact of the royalty buyout charge from Janssen, operating margin would have been 47%.
GILD FAQs
How does GILD typically perform around its earnings report dates?
Is Gilead Sciences, Inc. (GILD) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
GILD Earning Call Sentiment
Gilead Sciences, Inc. (GILD) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
GILD.O
2.45%Positive
The earnings call reveals strong financial performance, particularly in HIV and Oncology sales, alongside product margin improvements. The Q&A highlights optimism in product launches and market expansion, despite some management evasiveness on regulatory and payer issues. Shareholder returns are robust, and while EPS declined, product sales growth and optimistic guidance suggest positive momentum. Given these factors, the stock price is likely to experience a positive movement, although not exceptionally strong due to some uncertainties addressed in the Q&A.